Motley Fool Asset Management LLC Acquires 963 Shares of HealthEquity, Inc. (NASDAQ:HQY)

Motley Fool Asset Management LLC boosted its holdings in shares of HealthEquity, Inc. (NASDAQ:HQY) by 0.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 121,316 shares of the company’s stock after acquiring an additional 963 shares during the quarter. Motley Fool Asset Management LLC owned 0.14% of HealthEquity worth $8,043,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in HQY. McGlone Suttner Wealth Management Inc. acquired a new position in shares of HealthEquity in the 4th quarter worth approximately $29,000. DekaBank Deutsche Girozentrale acquired a new position in shares of HealthEquity during the 3rd quarter valued at $41,000. Fifth Third Bancorp lifted its position in shares of HealthEquity by 36.5% during the 3rd quarter. Fifth Third Bancorp now owns 602 shares of the company’s stock valued at $44,000 after acquiring an additional 161 shares during the period. Operose Advisors LLC acquired a new position in shares of HealthEquity during the 3rd quarter valued at $44,000. Finally, Covestor Ltd lifted its position in shares of HealthEquity by 92.9% during the 3rd quarter. Covestor Ltd now owns 1,119 shares of the company’s stock valued at $82,000 after acquiring an additional 539 shares during the period. 99.55% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

HQY has been the topic of a number of research reports. Bank of America boosted their target price on shares of HealthEquity from $93.00 to $97.00 and gave the company a “buy” rating in a research report on Wednesday, March 20th. Barrington Research reaffirmed an “outperform” rating and set a $100.00 price objective on shares of HealthEquity in a report on Friday, March 22nd. Barclays increased their price target on shares of HealthEquity from $84.00 to $104.00 and gave the stock an “overweight” rating in a report on Friday, February 23rd. JPMorgan Chase & Co. increased their price target on shares of HealthEquity from $86.00 to $108.00 and gave the company an “overweight” rating in a research report on Tuesday, April 2nd. Finally, Royal Bank of Canada raised their target price on shares of HealthEquity from $90.00 to $92.00 and gave the stock an “outperform” rating in a report on Wednesday, March 20th. One investment analyst has rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $96.17.

Insiders Place Their Bets

In other news, EVP Delano Ladd sold 2,499 shares of the company’s stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $80.00, for a total value of $199,920.00. Following the sale, the executive vice president now directly owns 49,996 shares of the company’s stock, valued at approximately $3,999,680. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In related news, EVP Delano Ladd sold 2,499 shares of the firm’s stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $80.00, for a total transaction of $199,920.00. Following the transaction, the executive vice president now directly owns 49,996 shares of the company’s stock, valued at $3,999,680. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Jon Kessler sold 33,765 shares of the business’s stock in a transaction that occurred on Friday, March 22nd. The stock was sold at an average price of $79.81, for a total transaction of $2,694,784.65. Following the completion of the transaction, the chief executive officer now directly owns 126,635 shares of the company’s stock, valued at approximately $10,106,739.35. The disclosure for this sale can be found here. Insiders sold a total of 71,322 shares of company stock worth $5,682,895 over the last quarter. Company insiders own 2.70% of the company’s stock.

HealthEquity Price Performance

HealthEquity stock traded down $0.16 during mid-day trading on Thursday, hitting $79.04. 596,788 shares of the company were exchanged, compared to its average volume of 600,952. The company has a debt-to-equity ratio of 0.43, a current ratio of 4.76 and a quick ratio of 4.76. The business’s 50 day simple moving average is $81.08 and its two-hundred day simple moving average is $74.41. The company has a market capitalization of $6.78 billion, a P/E ratio of 122.83, a PEG ratio of 1.30 and a beta of 0.53. HealthEquity, Inc. has a 12-month low of $48.86 and a 12-month high of $84.49.

HealthEquity (NASDAQ:HQY) last posted its earnings results on Tuesday, March 19th. The company reported $0.50 EPS for the quarter, beating the consensus estimate of $0.42 by $0.08. HealthEquity had a return on equity of 6.91% and a net margin of 5.57%. The company had revenue of $262.39 million during the quarter, compared to analyst estimates of $258.56 million. Analysts forecast that HealthEquity, Inc. will post 2.12 earnings per share for the current fiscal year.

HealthEquity Company Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.